Duchenne muscular dystrophy (DMD) causes severe disability of children and death of young men, with an 16 incidence of approximately 1/5,000 male births. Symptoms appear in early childhood, with a diagnosis made 17 around 4 years old, a time where the amount of muscle damage is already significant, preventing early 18 therapeutic interventions that could be more efficient at halting disease progression. In the meantime, the 19 precise moment at which disease phenotypes arise -even asymptomatically -is still unknown. Thus, there is a 20 critical need to better define DMD onset as well as its first manifestations, which could help identify early 21 disease biomarkers and novel therapeutic targets.
INTRODUCTION
specific markers of disease initiation in order to increase diagnosis sensitivity and, therefore, improve patient 48 management by accelerating their access to better healthcare; and 2) develop alternative therapeutic 49 approaches by finding targets that compensate the lack of dystrophin and complement current attempts at 50 restoring its expression (8).
51
In 2007, a seminal publication reported that the gene expression profile of muscles from asymptomatic DMD 52 children younger than 2 years old is already distinguishable from healthy muscles, suggesting that DMD 53 molecular dysregulations appear before disease symptomatic manifestations (4). Evidence obtained in 54 multiple animal models, such as neonatal GRMD dogs (9), DMD zebrafish (10) and mdx mouse embryos (11), as 55 well as in human foetuses (12) (13) (14) even suggest that DMD starts before birth, during prenatal development.
56
Our team recently identified the embryonic dystrophin isoform Dp412e expressed in early mesoderm-57 committed cells (15), another indication that DMD can start in utero. Further exploring DMD onset in human 58 foetuses is extremely challenging for obvious ethical and practical reasons. A way to overcome these issues is 59 to develop a human DMD model in vitro, recapitulating embryonic development from human pluripotent stem 60 cells to skeletal muscle lineages.
61
To our knowledge, none of the existing human DMD in vitro models, either based on tissue-derived myoblasts expression of the skeletal muscle program and especially before the expression of Dp427m, the muscle variant 142 of the DMD gene.
143
DMD hiPSC can become skeletal muscle progenitor cells, but exhibit specific muscle gene dysregulations 144 Healthy and DMD cells were in the skeletal muscle compartment at day 17, as evidenced by the expression of 145 multiple lineage-specific genes and proteins, such as transcription factors (e.g. MYOD1 (65)), cell surface 146 markers (e.g. CDH15 (66)), sarcomere genes (e.g. TNNC2 (67)), dystrophin-associated protein complex (DAPC) 147 genes (e.g. SGCA (68)), Calcium homeostasis genes (e.g. RYR1 (69)) and muscle-specific miRNAs (myomiR, e.g. 148 miR-1 (70)), ( Figure 1B , Table S2 ). They both showed an embryonic/foetal phenotype characterised by ERBB3 149 expression, in contrast with tissue-derived myoblasts that expressed NGFR (21). Here again, alternative cell 150 lineages were absent or greatly downregulated, such as tenocytes (MKX (71) and SCX (72)), chondrocytes 151 (SOX5 and SOX9 (73)), osteoblasts (SP7 (74) and SPP1 (75)) or nephron progenitors (SIX2 (76) and SALL1 (77)) 152 (Table S2 ).
153
Interestingly, DMD cells did not show dysregulated expression of skeletal muscle transcription factors (Table   154   S2 ). However, several myomiRs were found downregulated (e.g. miR-1, Figure 2C ), together with genes related 155 to calcium homeostasis (e.g. ATP2A2 (78), at both mRNA and protein level, Figure 2D -E) as well as members of 156 the DAPC (e.g. SNTA1 (79)) ( Table S2 ). Concerning cell lineages, there was no visible difference when extracts from DMD cells confirmed that dystrophin was either undetectable or slightly expressed ( Figure 3B ), 168 as in the corresponding patient muscle biopsies.
169
We selected representative mRNAs and miRNAs and showed that both hiPSC-derived and tissue-derived 170 myotubes have exited the cell cycle and upregulated genes expressed in skeletal muscles ( Figure S4A , Figure   171 4A, Table S2 ). This included skeletal muscle myomiRs (miR-1, miR-133 and miR-206 (80,81) ), transcription 172 factors involved in skeletal myogenesis including those of the MRF family (e.g. MYOD1 (65), MYOG (82)), 173 specific muscle cell surface markers (e.g. CDH15 (66), ITGA7 (83)) as well as genes involved in the formation of 174 the DAPC (e.g. SGCA (68), DTNA (84)), sarcomeres (e.g. TNNC2 (67), TNNT3 (85)), myofibril organisation (e.g. 175 UNC45B (86) , NACA (87)) and the execution of excitation-contraction coupling at the neuromuscular junction 176 (NMJ, e.g. MUSK (88) , DOK7 (89)) ( Figure 4A , Table S2 ).
177
Even though global analysis showed that hiPSC-derived myotubes were similar to their tissue-derived 178 counterparts in term of lineage commitment, they displayed an embryonic/foetal phenotype -as suggested in 179 progenitors at day 17. This can be illustrated by the expression of the embryonic/foetal myosin heavy/light 180 chains MYH3 (90), MYH8(91), MYL4 (92) and MYL5 (93) but not the postnatal transcripts MYH1 and MYH2 (94), 181 which were detected in tissue-derived myotubes. Myotubes derived from hiPSCs had also higher levels of IGF2, 182 which is downregulated at birth (95), and expressed DLK1, which is known to be extinct in adult muscles (96) 183 ( Figure S4B ).
184
Despite the embryonic/foetal phenotype, hiPSC-derived myotubes showed evidence of terminal 185 differentiation and cellular maturation. First, their total level of myosin heavy chain proteins was significantly 186 higher than in tissue-derived myotubes, as confirmed by Western blotting (Figure 3B ). RNAs and proteins 187 involved in DAPC formation (e.g. DMD, SGCA (68) and SGCG (97)), as well as in excitation-contraction coupling 188 (e.g. RYR1 (69) and CACNA1S / CAV1.1 (98)) were also present at higher levels ( Figure 3B-4A ). Finally, higher 189 expression of skeletal muscle transcription factors (e.g. MEF2C (99)), and of multiple genes involved in muscle 190 contraction (e.g. TNNT3 (85)), NMJ formation (e.g. RAPSN (100)), and creatine metabolism (e.g. CKM (101)) 191 indicates that hiPSC-derived cells expressed features of fully differentiated muscle cells ( Figure 4A ). Similar to 192 previous time points, day 25 cells were negative for markers of alternative muscle lineages, i.e. cardiac (miR-193 208a (102) , MYL7 (103) and RYR2 (104)) and smooth muscle cells (MYH11 (105), CNN1 (106) and 194 CHRNA3/B2/B4 (107)).
195
In DMD cells, there was a global trend toward downregulation of muscle transcription factors, which was only 196 significant for MEF2A and MEF2D in hiPSC-derived myotubes and EYA4 and MYOD1 in tissue-derived myotubes 197 ( Figure S4C ). In addition, myomiRs previously associated with muscle dystrophy (dystromiRs, e.g. miR-1 (70), 198 Figure 2C ) were found downregulated (Table S2) . Similarly, a global downregulation phenotype was observed 199 in both tissue-and hiPSC-derived DMD myotubes, and concerned multiple genes associated with known overexpression of ANGPT1 (114), CTGF (115), collagens (e.g. COL1A2 (116)), matrix metallopeptidases (MMPs) 217 and tissue inhibitors of metallopeptidase (TIMPs) (117) ( Figure 5B ). Conversely, the myomiR miR-133b that 218 controls CTGF expression (118) was repressed (Table S2) . Interestingly, gene members of the transforming 219 growth factor (TGF)-β pathway, a well-known inducer of fibrosis (119), were not found dysregulated (Figure   220   5B ).
221
Altogether, these data argue for fibrosis as an intrinsic feature of DMD skeletal muscle cells, rather than a 222 process solely driven by interstitial cell populations in the niche. Furthermore, this muscle-driven fibrosis 223 seems independent of the TGF-β pathway, and could rather depend on the SHH pathway, together with an 224 intrinsic upregulation of chondrocyte markers and collagens.
225
Mitochondria, a key organelle impacted by the absence of dystrophin prior calcium dysregulation
226
As previously described (120) and illustrated on Figure S5A , the energy metabolism of DMD hiPSC-derived 227 myotubes was dysregulated at the creatine and carbohydrate levels, up to the respiration ( Figure 6A -B, Figure   228 S2C). The creatine transporter was not impacted while mRNAs coding for enzymes of both creatine and 229 creatine phosphate biosynthesis were underrepresented. Neither glucose nor glutamate transporter 230 expression were impaired. However, glutamine biosynthesis (followed by gluconeogenesis that feeds glycolysis 231 from glutamine) as well as glycogenesis (followed by glycogenolysis that feeds glycolysis from glycogen) were 232 all downregulated, together with glycolysis itself. In contrast, the pentose phosphate pathway, which is in 233 parallel to glycolysis, was upregulated, especially the oxidative part. Pyruvate decarboxylation and generation 234 of acetyl-CoA to feed the tricarboxylic acid (TCA) cycle was also impaired. Finally, the TCA cycle itself ( Figure   235 6A, Figure S2C ) and the mitochondrial electron transport chain were downregulated Figure 6B , Figure S2C ).
236
This is particularly reinforced by lower levels of a member of the ATP synthase complex ATP5A1 at both mRNA 237 and protein levels ( Figure 6C -D). Moreover, transcripts encoded by the mitochondrial DNA and mitochondrial 238 DNA itself were decreased in DMD hiPSC-derived myotubes at day 25 ( Figure S5B-S5E ).
239
In the presented cell model, a significant downregulation of a mRNA set coding for mitochondrial proteins was 240 primarily observed at day 10 with the downregulation of 11 % (10 mRNAs, DMD/Healthy expression ratio ≤ 241 0.76, adjusted pvalue ≤ 0.05) of the mitochondrial outer membrane genes, and amplified during the 242 differentiation of DMD cells ( Figure 7A ). Therefore, defects depicted at day 25 rooted before the expression of 243 the skeletal muscle program at day 17. Among them, mRNA downregulation of TSPO, a channel-like molecule 244 involved in the modulation of mitochondrial transition pore (121), occurred from day 10 to day 25. This 245 downregulation was also observed at the protein level at day 17 ( Figure 7B ). Moreover, the protein import 246 system was affected from day 17 at both mRNA and protein levels ( Figure S5C -S5F). Simultaneously, mRNAs 247 involved in mitochondrial genome transcription started to be downregulated, followed by genes involved in 248 mitochondrial DNA replication at day 25 ( Figure S5D-S5G ). This progressive increase of dysregulations was also 249 observed at the level of the entire mRNA set related to mitochondria (around 1,000 mRNAs) as illustrated by 250 the volcano plots as well as the gene ontology enrichments ( Figure 7C , Figure S2C ).
251
Our data highlight early impairments in genes coding for mitochondria that start at the somite stage -prior 252 calcium homeostasis dysregulation -and increase with the differentiation in an orderly manner. These 253 elements complete the mitochondrial DMD phenotype described at the myotube stage.
254
Altogether, our study demonstrates that DMD starts prior to the expression of well-described markers of 255 muscle differentiation. It shows that hiPSC-based experimental models of DMD can help identify early disease 256 manifestations and stratify multiple pathological features over the course of muscle development.
Since the discovery of the DMD gene in 1987 (1), DMD cellular phenotypes were considered under the unique 259 scope of a "mechanical hypothesis" in which dystrophin deficiency led to membrane leakage and ultimately 260 muscle cell rupture. However, over the last 15-20 years, studies have brought unequivocal evidence that 261 multiple additional factors are in play, such as calcium intracellular overloads (122, 123) , excessive oxidative 262 stress (124,125), metabolic switches (126,127) , as well as an overall tissue context where aberrant interactions 263 between resident cells lead to inflammation and fibro-adipogenesis (128) (129) (130) . This has progressively led to a 264 complex picture involving interdependent homeostatic perturbations and to date, the identification of 265 prevalent pathological features driving the initiation of DMD is hardly feasible.
266
The skeletal myogenesis modelled here by the differentiation of hiPSCs, without gene overexpression or cell 267 sorting, homogeneously and robustly recapitulates key developmental steps -pluripotency, mesoderm, 268 somite and skeletal muscle -without any trace of other lineages. Therefore, it is a suitable dynamic model for 269 studying human skeletal muscle development in both healthy and DMD cells, offering the possibility to clarify 270 the consequences of the absence of dystrophin at each step of the differentiation process, as well as to 271 explore dystrophin functions and find earlier and more specific disease biomarkers.
272
As previously observed with pluripotent stem cells (131) 
279
In qualitative terms, DMD hiPSC-derived myotubes showed an overall morphology similar to healthy controls, 280 with cell fusion and clear striation patterns, suggesting that the potential impact of dystrophin during in vitro 281 differentiation is subtle and does not prevent myotube formation. However, our unbiased mRNA-seq analysis 282 highlighted striking transcriptome dysregulations with 3,578 differentially expressed genes at day 25. This 283 includes numerous genes which can be linked to previously described DMD phenotypes such as 1) DAPC 284 dissociation (132); 2) rupture of calcium homeostasis (122); 3) myomiR downregulation (70,133); 4) sarcomere 285 destabilisation (134-136); 5) mitochondrial and metabolism dysregulations (126,127); 6) NMJ fragmentation 286 (137, 138) and 7) fibrosis (130, 139) . It is interesting to note that these phenotypes are already detected at the 287 transcriptional level in embryonic/foetal myotubes, while they usually appear postnatally in Human and other 288 animal models. In addition, most of them are often considered as consequences of degeneration-regeneration 289 cycles typical of DMD muscles in vivo (135, 140, 141) which are absent in our in vitro model, indicating that a 290 part of these defects are primarily due to the absence of dystrophin itself. In particular, our data suggest that 291 fibrosis is an intrinsic feature of DMD skeletal muscle cells, and therefore, it does not absolutely require a 292 specific tissue context or additional cell populations to be detected in vitro. Fibrosis is a major hallmark of 293 DMD pathophysiology, and the regulation of this process has been largely investigated in the past (119, 142) . A 294 long-debated question is the implication of the TGFβ signalling pathway (143). In our model, TGFβ signalling 295 was inhibited up to day 17 by inhibitors in the cell culture media, and TGFβ-related genes were not 296 upregulated at day 25, suggesting that the observed fibrosis is TGFβ-independent.
297
Since several studies on Human and other animal models had described dystrophic phenotypes in DMD 298 foetuses/infants (9-14), we investigated the precise timing of disease onset in our hiPSC-derived myotubes.
299
First, the absence of dystrophin does not modify the capacity of cells derived from adult tissue biopsies to be 300 reprogramed using the approach developed by Takeshi and Yamanaka (144) . Both healthy and DMD cells 301 retained pluripotency and the capacity to enter the mesoderm compartment at day 3. At that time, the 302 embryonic dystrophin Dp412e is expressed and only marginal dysregulations are observed in DMD cells, a priori unrelated to cell fate choice as cells only express paraxial mesoderm markers at level similar to healthy 304 controls.
305
DMD dysregulations are greatly increased at day 10, when cells express somite markers without any trace of 306 transcripts coding for the long dystrophin isoform Dp427m expressed in skeletal muscles (only the ubiquitous 307 variant Dp71-40 is found). At that time, we noticed few significant dysregulations of cell lineage markers, 308 which became more prevalent at day 17 and 25. This might be an indication that to some extent, cell fate is 309 misguided in DMD cells, where skeletal muscle markers are underexpressed and replaced by markers of 310 alternative lineages, such as chondrocytes.
311
First visible at day 10, we identified mitochondrial dysregulation as one of the key processes happening in an 312 orderly manner. Interestingly, early observations prior the discovery of the DMD gene had hypothesised that 313 DMD was a mitochondrial/metabolic disease based on protein quantifications and enzyme activities (126,145).
314
Later, mitochondria was identified as a key organelle in DMD, responsible for metabolic perturbations but also 315 calcium accumulation and generation of reactive oxygen species (122) (123) (124) (125) . In this study, numerous genes 316 coding for proteins located in the outer mitochondrial membrane start to be downregulated from day 10 in 317 DMD cells, such as the benzodiazepine receptor TSPO, a member of the controversial mitochondrial 318 permeability transition pore (mPTP) (121). The mPTP is a multiprotein complex whose members are not all 319 precisely identified, and several studies suggest that it might be involved in DMD pathophysiology (146, 147) . A 320 chicken-and-egg question currently debated relates to the initiation of these homeostatic breakdowns, as 321 positive feedbacks exist between mitochondria, oxidative stress and calcium homeostasis dysregulations 322 (123, 124) . In our model, dysregulations of genes controlling calcium homeostasis were detected after day 10, 323 suggesting that mitochondrial impairment starts early and has predominant consequences in DMD, as 
334
Moreover, several myomiRs were found downregulated at days 17 and 25 and seem to play a central part in 335 multiple DMD phenotypes. Besides their role in myogenesis (80,81), myomiRs can be involved in calcium 336 homeostasis (150), metabolism and mitochondrial functions (151,152), and fibrosis (118, 153) . In particular, 337 miR-1 and miR-206 are known to target key genes such as CACNA1C (150), CTGF (118), RRBP1 (153), several 338 regulators of the pentose phosphate pathway (151), and even transcripts encoded by the mitochondrial 339 genome (152). Even though the functional consequences of the multiple gene and myomiR dysregulations 340 highlighted in this study is virtually impossible to anticipate, we believe that myomiRs can be key players in 341 DMD biology.
342
Only few studies argued that DMD starts before the expression of the muscular dystrophin protein (18,154).
343
Our data supports this idea as disease phenotypes seem to be initiated at the somite stage where Dp427m was 344 not even transcribed. This could be explained by the deficit in other dystrophin isoforms expressed prior day 345 10, such as Dp412e at day 3 (15), but also by the decrease or loss of other RNA products expressed from the 346 DMD locus, such as the ubiquitous isoform Dp71-40 or long non-coding RNAs (155). The lack of knowledge 347 around these additional products contrasts with the extensive amount of data on the structure and function of 348 the main muscular isoform Dp427m whose most studied role is to stabilise muscle cell membrane during 349 contraction (156). Other tissue specific isoforms have been described, e.g. in the retina (Dp260 (30)) and in the 350 brain (Dp427c (31), Dp427p (29) and Dp140 (28)), some of which are also slightly expressed in skeletal muscles 351 under certain circumstances (157), but their role remains mostly unknown. Interestingly, in our data, the expression of Dp260 follows the same pattern of expression as Dp427m. It has been shown that the expression 353 of Dp260 in mdx/utrnK/K mice can rescue the mdx phenotype (158) 
357
To date, the standard of care for DMD patients helps mitigate and delay some of the most severe symptoms 358 but remains insufficient to have a curative effect. Despite decades of work with the mdx mouse model, only a 359 few pharmacological candidate molecules have moved forward to clinical trials, with variable efficiency. As 360 several gene therapy trials have been recently initiated with promising preliminary data, we believe that our 361 human in vitro model system might be useful for the development of combination therapies. Recent studies 362 have proved that the association of two different therapeutic approaches could have a synergistic effect on 363 the overall treatment outcome, and can be used for instance to boost the effect of dystrophin re-expression by 364 antisense oligonucleotides or gene therapy (8, 160, 161) . Here, our extensive RNA-seq data could help identify 365 relevant therapeutic targets for pharmacological intervention, such as CTGF -involved in fibrosis and found 366 upregulated in DMD myotubes -which can be inhibited by monoclonal antibodies (162) as well as fibrosis. Altogether, these data argue for 1) a deficit and not a delay in DMD differentiation; 2) each primer set was preliminarily determined by running a standard curve. Detection was performed using a 
450
Sequencing is then carried out on paired-end 100 b/75 b of Illumina HiSeq 4000.
451
An RNA-seq analysis workflow was designed using snakemake 3.5.4 (165) for read quality estimation, mapping 452 and differential expression analysis. Quality estimation was obtained with FastQC 0.11.5 453 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Mapping to the human genome assembly 454 Ensembl GRCh37.87 (43,695 transcripts) was performed with STAR 2.5.0a (166). According to STAR manual and 455 for more sensitive novel junction discovery, the junctions detected in a first round of mapping were used in a 456 second mapping round. Read strandness was confirmed using RSeQC (167) High-throughput data analyses -Graphs were realised using RStudio. Viridis library (175) was used for the colour palette easier to read with colour blindness and print well in grey scale. For unsupervised analyses, 485 normalised counts were standardised with scale function (center = TRUE, scale = TRUE) and plotted with 486 corrplot function from corrplot library (176). Spearman correlation was done with the cor function (method = 487 "spearman", use = "pairwise.complete.obs") on standardised data. Hierarchical clustering and heatmap were 488 performed with gplots library (177) 
